Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy

AZ fleshes out positive trial of revitalised lupus drug anif...

Gilead says arthritis drug filgotinib fails in follow-up use...

GSK buys Avalon-partnered Sitari and its coeliac drug

Genentech’s Rituxan approved for rare skin disease

The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.